# Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

> **NCT02218723** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF UD-DPI
- **DRUG:** FF ELLIPTA DPI

## Key facts

- **NCT ID:** NCT02218723
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-28
- **Primary completion:** 2014-12-19
- **Final completion:** 2014-12-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218723, "Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02218723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*